# A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects

> **NCT00449527** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 123 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide/formoterol pMDI
- **DRUG:** Budesonide HFA pMDI

## Key facts

- **NCT ID:** NCT00449527
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00449527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00449527, "A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00449527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*